PTPRC and stroke disorder: We assume that optimal timing for the therapy would be the moment of the highest levels of the endogenous CD45–CD34 + CD271+ cells observed in the peripheral blood of stroke patients, which could reflect the increased release of the cells from bone marrow to peripheral blood in response to ischemic lesion mediators.